Strategy Set to Report Q4 Earnings: Buy, Sell or Hold the Stock?
zacks.com
Want to monitor NKTX?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor NKTXNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body.